Get the Stockscreener App
41.43
14.19%
5.12
Corcept Therapeutics Inc stock is traded at $41.43, with a volume of 3.34M.
It is up +14.19% in the last 24 hours and down -51.28% over the past month.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.
See More
Previous Close:
$36.31
Open:
$41.505
24h Volume:
3.34M
Relative Volume:
2.27
Market Cap:
$4.37B
Revenue:
$628.56M
Net Income/Loss:
$141.82M
P/E Ratio:
32.88
EPS:
1.26
Net Cash Flow:
$142.60M
1W Performance:
+17.16%
1M Performance:
-51.28%
6M Performance:
-39.98%
1Y Performance:
-29.76%
1-Day Range:
$40.46
$43.50
1-Week Range:
$33.80
$43.50
52-Week Range:
$32.99
$117.33
Corcept Therapeutics Inc Stock (CORT) Company Profile
Name
Corcept Therapeutics Inc
Sector
Industry
Phone
650.688.8803
Address
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
Compare CORT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CORT
Corcept Therapeutics Inc
|
41.50 | 3.82B | 628.56M | 141.82M | 142.60M | 1.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.24 | 117.00B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
756.53 | 78.75B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
821.22 | 50.52B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
375.82 | 48.28B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.56 | 37.81B | 4.98B | 69.59M | 525.67M | 0.5197 |
Corcept Therapeutics Inc Stock (CORT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-31-25 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Dec-16-25 | Initiated | UBS | Neutral |
| Nov-18-25 | Initiated | Wolfe Research | Peer Perform |
| Nov-06-23 | Upgrade | Truist | Hold → Buy |
| Apr-11-23 | Initiated | SVB Securities | Market Perform |
| Apr-04-23 | Initiated | Piper Sandler | Overweight |
| Feb-15-23 | Downgrade | Jefferies | Buy → Hold |
| Aug-01-22 | Downgrade | Truist | Buy → Hold |
| Jul-27-22 | Upgrade | Jefferies | Hold → Buy |
| Jun-27-22 | Resumed | Canaccord Genuity | Buy |
| Feb-02-22 | Initiated | Canaccord Genuity | Buy |
| Jan-28-22 | Initiated | Truist | Buy |
| Aug-05-20 | Downgrade | Jefferies | Buy → Hold |
| Sep-24-19 | Initiated | Jefferies | Buy |
| Sep-06-19 | Initiated | H.C. Wainwright | Buy |
| Feb-04-19 | Downgrade | B. Riley FBR | Buy → Neutral |
| Aug-10-18 | Reiterated | Stifel | Hold |
| May-31-18 | Downgrade | Stifel | Buy → Hold |
| Mar-09-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Aug-31-17 | Initiated | Stifel | Buy |
| Feb-02-17 | Initiated | Ladenburg Thalmann | Buy |
| Apr-21-15 | Initiated | FBR Capital | Outperform |
| Jan-13-14 | Downgrade | Stifel | Buy → Hold |
| Aug-09-13 | Downgrade | Janney | Buy → Neutral |
| Aug-09-13 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Feb-21-12 | Reiterated | JMP Securities | Mkt Outperform |
| Jan-06-10 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jul-17-08 | Initiated | Rodman & Renshaw | Mkt Outperform |
| Jun-21-07 | Upgrade | Punk, Ziegel & Co | Mkt Perform → Accumulate |
View All
Corcept Therapeutics Inc Stock (CORT) Latest News
Eagle Bancorp Posts Upbeat Q4 Results, Joins Corcept Therapeutics, LSI Industries And Other Big Stocks Moving Higher On Thursday - Benzinga
Why This Former Highflying Biotech Just Surged Again - Investor's Business Daily
Corcept Therapeutics (CORT) Surges 25% on Positive Trial Results - GuruFocus
Corcept posts trial win for ovarian cancer therapy (CORT:NASDAQ) - Seeking Alpha
Overall survival primary endpoint met in Corcept's pivotal phase 3 ROSELLA trial of relacorilant in patients with platinum-resistant ovarian cancer - marketscreener.com
Corcept Therapeutics stock soars after cancer drug meets survival endpoint By Investing.com - Investing.com Canada
In ROSELLA trial, relacorilant added 4.1 months survival in ovarian cancer - Stock Titan
Overall Survival Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer - Business Wire
QRG Capital Management Inc. Has $649,000 Stake in Corcept Therapeutics Incorporated $CORT - MarketBeat
CORT INVESTIGATION ALERT: Investigation Launched into Corcept Therapeutics (CORT), Hagens Berman Encourages Investors to Contact Firm - PR Newswire
Market Overview: Should you avoid Corcept Therapeutics Incorporated stock right nowWeekly Risk Report & Verified Momentum Watchlists - baoquankhu1.vn
Rally Mode: Will Corcept Therapeutics Incorporated stock hit new highs in YEAR2025 Risk Factors & Verified Short-Term Plans - baoquankhu1.vn
Corcept Therapeutics (CORT) Faces Investor Scrutiny Amid Receipt of FDA Complete Response Letter For Relacorilant, Shares Tank 50% – Hagens Berman - GlobeNewswire Inc.
Zacks Research Has Negative Forecast for CORT Q3 Earnings - MarketBeat
CORT Stock Price, Forecast & Analysis | CORCEPT THERAPEUTICS INC (NASDAQ:CORT) - Chartmill
Is Corcept Therapeutics Incorporated (CORT) The Most Promising Growth Stock According to Analysts? - Finviz
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Corcept Therapeutics Incorporated (CORT) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics IncorporatedCORT - PR Newswire
Corcept Therapeutics (NASDAQ:CORT) Lowered to Strong Sell Rating by Zacks Research - MarketBeat
One Rare Disease Biotech Posts 97% Margins but the Faster Growing Rival Just Turned Its First Profit - Yahoo Finance
Corcept Therapeutics (NASDAQ:CORT) Nasdaq Composite Mechanism Strategy - Kalkine Media
CORT Investors Have Opportunity to Join Corcept Therapeutics Inc - GuruFocus
Corcept Therapeutics Under Investigation After FDA Response, Shares Plunge Over 50% - Intellectia AI
CORT Investors Have Opportunity to Join Corcept Therapeutics Incorporated Fraud Investigation with the Schall Law Firm - PR Newswire
Corcept Therapeutics Faces Investigation After FDA Response Letter, Shares Plunge Over 50% - Intellectia AI
DJS Law Group Investigates Corcept Therapeutics for Securities Violations - Intellectia AI
Corcept Therapeutics Incorporated Investigated on Behalf of InvestorsContact the DJS Law Group to Discuss Your Rights – CORT - marketscreener.com
INVESTOR ALERT: Investigation of Corcept Therapeutics Incorporated (CORT) by Holzer & Holzer, LLC - GlobeNewswire
Corcept’s growth hopes dented after FDA rebuff for Cushing’s drug - S&P Global
Corcept Therapeutics (CORT) Faces Investor Scrutiny Amid Receipt of FDA Complete Response Letter For Relacorilant, Shares Tank 50%Hagens Berman - PR Newswire
Corcept Therapeutics (BIT:1CORT) Price Target Decreased by 24.29% to 80.62 - Nasdaq
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept ... - Bluefield Daily Telegraph
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AST SpaceMobile, Inc. - GlobeNewswire Inc.
CORT INVESTIGATION: Corcept Therapeutics Investors Should Contact Block & Leviton LLP To Potentially Recover Losses - TradingView — Track All Markets
Inflation Data: Why is Corcept Therapeutics Incorporated stock going upJuly 2025 Opening Moves & Weekly Breakout Watchlists - baoquankhu1.vn
Scott+Scott Attorneys at Law LLP Announces Its Investigation Into Corcept Therapeutics Incorporated (CORT) - marketscreener.com
Bank Watch: Why is Corcept Therapeutics Incorporated stock going upWeekly Volume Report & Expert Curated Trade Ideas - baoquankhu1.vn
CORT Investor ALERT: Corcept Therapeutics Inc. Investigated for Securities Fraud; Investors ... - bdtonline.com
CORT Investor ALERT: Corcept Therapeutics Inc. Investigated - GlobeNewswire
Corcept Insider Transaction Explained After Shares Tumble 50% in One Day - Yahoo Finance
Why Corcept (CORT) stock is trading lower today - MSN
Bronstein, Gewirtz & Grossman, LLC Is Investigating Corcept Therapeutics Incorporated (CORT) And Encourages Stockholders to Connect - ACCESS Newswire
H.C. Wainwright lifts Corcept stock target to $115 on drug outlook - MSN
Scott+Scott Attorneys at Law LLP Reminds Investors of Its Investigation Into Corcept Therapeutics Incorporated (NASDAQ: CORT) - Business Wire
Will Corcept Therapeutics Incorporated (HTD) stock outperform benchmarksWeekly Market Outlook & AI Powered Buy/Sell Recommendations - ulpravda.ru
Price Targets Lowered on Corcept Therapeutics (CORT) After FDA Letter - Finviz
Corcept Therapeutics (CORT) Faces Investor Scrutiny Amid - GlobeNewswire
Is Corcept Therapeutics Incorporated stock positioned for long term growthJuly 2025 Rallies & Capital Protection Trading Alerts - ulpravda.ru
Insider Sell: William Guyer Sells 20,000 Shares of Corcept Thera - GuruFocus
Corcept Therapeutics (CORT): Analyst says shares pricing in growth, new launch - MSN
Insider Selling: Corcept Therapeutics (NASDAQ:CORT) Insider Sells 20,000 Shares of Stock - MarketBeat
Corcept Therapeutics Inc Stock (CORT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Corcept Therapeutics Inc Stock (CORT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Guyer William | Chief Development Officer |
Jan 06 '26 |
Sale |
35.18 |
20,000 |
703,656 |
1,235 |
1.15%
0.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):